Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui (September 29, 2026 ) by James Waldron Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China. The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor agonist.
By Ross Youngs, September 28, 2026 About 20,000 Genes Can’t Explain You. Here’s What Does the Rest of the Work Most of Biology’s Control Chemistry Still Has No Name In May 2000, some of the best geneticists in the world gathered at Cold Spring Harbor Laboratory, and in a bar they started betting on how many genes it takes to
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases (August 31, 2026 ) by Eli Lilly and Company Merida’s antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile
Colossal AI spinoff hits $3.8 billion valuation, targets aging with first model (August 20, 2026 ) by Sasha Richie Astromech just announced new funding to develop artificial intelligence that can predict biological outcomes. Astromech, an artificial intelligence venture gestated at Dallas’ resident sci-fi startup, secured $20 million in new funding at a $3.8 billion valuation, the company announced Thursday. Founded
